Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
gptkb:monoclonal_antibody |
| gptkbp:administeredBy |
subcutaneous injection
|
| gptkbp:approvalYear |
2017
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
gptkb:R03DX10
|
| gptkbp:brand |
gptkb:Fasenra
|
| gptkbp:CASNumber |
gptkb:1044511-01-3
|
| gptkbp:developedBy |
gptkb:AstraZeneca
|
| gptkbp:drugClass |
gptkb:anti-interleukin-5_receptor_monoclonal_antibody
|
| gptkbp:eliminationHalfLife |
15-20 days
|
| gptkbp:hasMolecularFormula |
C6508H10004N1732O2032S46
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
induces apoptosis of eosinophils
|
| gptkbp:pregnancyCategory |
not assigned (consult physician)
|
| gptkbp:routeOfAdministration |
subcutaneous
|
| gptkbp:sideEffect |
headache
injection site reaction pharyngitis |
| gptkbp:target |
gptkb:interleukin-5_receptor_alpha_(IL-5Rα)
|
| gptkbp:UNII |
3ZJ8Q3183V
|
| gptkbp:usedFor |
severe eosinophilic asthma
|
| gptkbp:bfsParent |
gptkb:IL5
|
| gptkbp:bfsLayer |
6
|
| https://www.w3.org/2000/01/rdf-schema#label |
benralizumab
|